Health Discovery Corporation (OTCBB: HDVY) is pleased to announce that it has recently received notices of allowance in two of its patent applications covering the Company’s SVM-RFE technology. The first notice was issued by the United States Patent and Trademark Office for a continuation application that was filed to further expand the scope of coverage of the RFE algorithm. The allowed claims cover all uses of the SVM-RFE algorithm, including but not limited to its use in biomarker discovery. The second notice of allowance was issued by the Canadian Intellectual Property Office for claims covering the use of SVM-RFE for biomarker discovery. Once issued, this will be the Company’s second Canadian patent covering SVM-RFE. The first patent, which issued in late 2010, like the newly allowed U.S. application, is not limited to any specific data type thereby covering all applications of the SVM-RFE technology.
With the issuance of the recently allowed patents, the Company will own three U.S. patents, two Australian patents, two Canadian patents, one European patent and one Japanese patent covering the SVM-RFE algorithm. Still pending are one U.S. patent application, which was filed to provoke an interference with Intel Corporation (NASDAQ: INTC), one Japanese application and one European application.
This minefield of patents covering the SVM-RFE created by Health Discovery Corporation puts the Company in the unique position of being able to control usage of the technology in most countries in which uses of the technology have been reported.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relating to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop or commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.